Evergreen Therapeutics recently announced that the first patient has been enrolled in its Phase II clinical trial in the United States for its investigational drug EG-501. The trial is evaluating EG-501, an oral small-molecule therapy, for the treatment of cognitive impairment associated with Neuropsychiatric Systemic Lupus Erythematosus (NPSLE).
It is estimated that approximately 56% of patients with systemic lupus erythematosus (SLE) may develop cognitive impairment within one year, manifesting as symptoms such as memory lapses, aphasia, and other deficits, yet targeted therapeutic options have long been unavailable.
Enrolled participants will enter a 12-week dosing period and receive either the assigned dose of the investigational drug or placebo according to randomization, until the protocol-specified 12-week assessment timepoint. The trial’s primary endpoint is the change in RBANS score from baseline to the study endpoint (Week 12).